DK0668863T3 - Quinuclidinderivat som substans P-antagonist - Google Patents

Quinuclidinderivat som substans P-antagonist

Info

Publication number: DK0668863T3
Authority: DK; Denmark
Prior art keywords: pct; substance; antagonist; quinuclidine derivative; date
Prior art date: 1992-11-12

Application number

DK93917176.5T

Other languages

Danish (da)

English (en)

Inventor

Fumitaka Ito

Hiroshi Kondo

Masami Nakane

Kaoru Shimada

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-12

Filing date

1993-07-19

Publication date

1997-06-30

1993-07-19 Application filed by Pfizer filed Critical Pfizer

1997-06-30 Application granted granted Critical

1997-06-30 Publication of DK0668863T3 publication Critical patent/DK0668863T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK93917176.5T 1992-11-12 1993-07-19 Quinuclidinderivat som substans P-antagonist DK0668863T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US97524492A	1992-11-12	1992-11-12

Publications (1)

Publication Number	Publication Date
DK0668863T3 true DK0668863T3 (da)	1997-06-30

Family

ID=25522825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93917176.5T DK0668863T3 (da)	1992-11-12	1993-07-19	Quinuclidinderivat som substans P-antagonist

Country Status (19)

Country	Link
US (1)	US5886009A (fr)
EP (1)	EP0668863B1 (fr)
JP (1)	JP2668164B2 (fr)
KR (1)	KR950704311A (fr)
CN (1)	CN1034732C (fr)
AT (1)	ATE147385T1 (fr)
AU (1)	AU676489B2 (fr)
CA (1)	CA2149242C (fr)
DE (1)	DE69307340T2 (fr)
DK (1)	DK0668863T3 (fr)
ES (1)	ES2096312T3 (fr)
FI (1)	FI934983L (fr)
GR (1)	GR3022459T3 (fr)
IL (1)	IL107495A (fr)
MX (1)	MX9307062A (fr)
MY (1)	MY130145A (fr)
NZ (1)	NZ254604A (fr)
WO (1)	WO1994011368A1 (fr)
ZA (1)	ZA938421B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6387925B1 (en) *	1999-06-01	2002-05-14	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) *	1999-06-22	2001-07-17	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
DE10001785A1 (de) *	2000-01-18	2001-07-19	Boehringer Ingelheim Pharma	NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms
EP1299393A2 (fr)	2000-07-11	2003-04-09	Bristol-Myers Squibb Pharma Company	Tetrahydroisoquinoleines 4-phenyle substituees et leur utilisation therapeutique
US6861526B2 (en)	2002-10-16	2005-03-01	Pfizer Inc.	Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
CA2547283C (fr) *	2003-11-26	2010-11-09	Pfizer Products Inc.	Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
NZ548236A (en) *	2004-01-30	2010-02-26	Pfizer Prod Inc	Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives
CN101119969B (zh)	2004-07-15	2014-04-09	阿尔巴尼分子研究公司	芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
NZ565111A (en)	2005-07-15	2011-10-28	Amr Technology Inc	Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2008039327A2 (fr)	2006-09-22	2008-04-03	Merck & Co., Inc.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh)	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
WO2008084261A1 (fr)	2007-01-10	2008-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
JP5501227B2 (ja)	2007-06-27	2014-05-21	メルク・シャープ・アンド・ドーム・コーポレーション	ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
JP2011515343A (ja)	2008-03-03	2011-05-19	タイガーファーマテック	チロシンキナーゼ阻害薬
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (fr)	2009-04-01	2012-09-19	Merck Sharp & Dohme	Inhibiteurs de l'activité akt
ES2662072T3 (es)	2009-05-12	2018-04-05	Albany Molecular Research, Inc.	7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
CN102638982B (zh)	2009-05-12	2015-07-08	百时美施贵宝公司	(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
US9034899B2 (en)	2009-05-12	2015-05-19	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
NZ599343A (en)	2009-10-14	2014-05-30	Merck Sharp & Dohme	Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (fr)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP2601293B1 (fr)	2010-08-02	2017-12-06	Sirna Therapeutics, Inc.	Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
CA2807307C (fr)	2010-08-17	2021-02-09	Merck Sharp & Dohme Corp.	Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en)	2010-09-01	2015-02-03	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (fr)	2010-09-16	2012-03-22	Schering Corporation	Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US9351965B2 (en)	2010-12-21	2016-05-31	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
JP2014514321A (ja)	2011-04-21	2014-06-19	メルク・シャープ・アンド・ドーム・コーポレーション	インスリン様増殖因子１受容体阻害剤
EP2770987B1 (fr)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Nouveaux composés qui sont des inhibiteurs d'erk
US20150299696A1 (en)	2012-05-02	2015-10-22	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru)	2012-09-28	2018-07-06	Мерк Шарп И Доум Корп.	Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
ME02925B (fr)	2012-11-28	2018-04-20	Merck Sharp & Dohme	Compositions et procédés pour traiter le cancer
MX373639B (es)	2012-12-20	2020-05-04	Merck Sharp & Dohme	Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
WO2019094312A1 (fr)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2020033282A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
MX2021001486A (es)	2018-08-07	2021-07-15	Merck Sharp & Dohme Llc	Inhibidores prmt5.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990005525A1 (fr) *	1988-11-23	1990-05-31	Pfizer Inc.	Derives de quinuclidine en tant qu'antagonsites de substance p
US5451586A (en) *	1990-06-01	1995-09-19	Pfizer Inc.	3-amino-2-aryl quinuclidines
WO1992021677A1 (fr) *	1991-05-31	1992-12-10	Pfizer Inc.	Derives de quinuclidine
EP0916346A3 (fr) *	1991-09-20	2000-12-06	Glaxo Group Limited	Recepteurs antagonistes NK-1 et recepteurs antagonistes 5HT3 pour le traitement des vomissements
US5340826A (en) *	1993-02-04	1994-08-23	Pfizer Inc.	Pharmaceutical agents for treatment of urinary incontinence

1993
- 1993-07-19 EP EP93917176A patent/EP0668863B1/fr not_active Expired - Lifetime
- 1993-07-19 ES ES93917176T patent/ES2096312T3/es not_active Expired - Lifetime
- 1993-07-19 AT AT93917176T patent/ATE147385T1/de not_active IP Right Cessation
- 1993-07-19 DE DE69307340T patent/DE69307340T2/de not_active Expired - Fee Related
- 1993-07-19 NZ NZ254604A patent/NZ254604A/en unknown
- 1993-07-19 JP JP6502707A patent/JP2668164B2/ja not_active Expired - Lifetime
- 1993-07-19 WO PCT/US1993/006624 patent/WO1994011368A1/fr active IP Right Grant
- 1993-07-19 AU AU46780/93A patent/AU676489B2/en not_active Ceased
- 1993-07-19 KR KR1019950701877A patent/KR950704311A/ko not_active Ceased
- 1993-07-19 US US08/500,958 patent/US5886009A/en not_active Expired - Fee Related
- 1993-07-19 DK DK93917176.5T patent/DK0668863T3/da active
- 1993-07-19 CA CA002149242A patent/CA2149242C/fr not_active Expired - Fee Related
- 1993-11-04 IL IL10749593A patent/IL107495A/en not_active IP Right Cessation
- 1993-11-09 MY MYPI93002345A patent/MY130145A/en unknown
- 1993-11-11 CN CN93114371A patent/CN1034732C/zh not_active Expired - Fee Related
- 1993-11-11 FI FI934983A patent/FI934983L/fi unknown
- 1993-11-11 ZA ZA938421A patent/ZA938421B/xx unknown
- 1993-11-11 MX MX9307062A patent/MX9307062A/es not_active IP Right Cessation
1997
- 1997-01-31 GR GR970400170T patent/GR3022459T3/el unknown

Also Published As

Publication number	Publication date
US5886009A (en)	1999-03-23
AU676489B2 (en)	1997-03-13
MX9307062A (es)	1994-05-31
JP2668164B2 (ja)	1997-10-27
CN1091134A (zh)	1994-08-24
GR3022459T3 (en)	1997-04-30
ES2096312T3 (es)	1997-03-01
DE69307340D1 (de)	1997-02-20
KR950704311A (ko)	1995-11-17
CA2149242A1 (fr)	1994-05-26
IL107495A0 (en)	1994-02-27
FI934983A7 (fi)	1994-05-13
NZ254604A (en)	1997-06-24
FI934983L (fi)	1994-05-13
IL107495A (en)	1998-12-27
EP0668863B1 (fr)	1997-01-08
WO1994011368A1 (fr)	1994-05-26
ATE147385T1 (de)	1997-01-15
AU4678093A (en)	1994-06-08
ZA938421B (en)	1995-05-11
MY130145A (en)	2007-06-29
CN1034732C (zh)	1997-04-30
FI934983A0 (fi)	1993-11-11
EP0668863A1 (fr)	1995-08-30
DE69307340T2 (de)	1997-04-24
CA2149242C (fr)	1998-08-04
JPH07508731A (ja)	1995-09-28

Publication	Publication Date	Title
DK0668863T3 (da)	1997-06-30	Quinuclidinderivat som substans P-antagonist
FI935134A0 (fi)	1993-11-19	Substituerade 3-aminokinuklidiner
BRPI0108977B8 (pt)	2021-05-25	compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
UA27776C2 (uk)	2000-10-16	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
MY107157A (en)	1995-09-30	Quinuclidine derivatives.
DK0687268T3 (da)	1998-10-12	Spiroazacykliske derivater som substans P-antagonister
DE69427704D1 (de)	2001-08-16	Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
ATE141792T1 (de)	1996-09-15	Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
ATE175114T1 (de)	1999-01-15	Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
ATE269865T1 (de)	2004-07-15	Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
DE69824313D1 (de)	2004-07-08	Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
NO953892D0 (no)	1995-09-29	Imidazolokinoksalinon-derivater som EAA-antagonister
ATE216891T1 (de)	2002-05-15	Verwendung von immunosuppressiva zur behandlung der schizophrenie
NO950177D0 (no)	1995-01-17	Farmakologisk aktive erivater
DK0648117T3 (da)	1998-02-23	Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
ATE232848T1 (de)	2003-03-15	Benzoesäurederivate und deren medizinische verwendung
NO951865L (no)	1995-05-11	Quinuclidin-derivat som substans-P antagonist
SE9502877D0 (sv)	1995-08-18	Novel opioid peptides